A J Kazimi bought $833 of CPIX
Chairman and CEO at CUMBERLAND PHARMACEUTICALS INC. 186 shares at an average of $4.48, traded Apr 1, 2025, filed May 9, 2025.
Score components
- +25RoleCEO
- 0Trade size$833 at market
- -5Relative to holdingsUnder 1% of holdings (0.0%)
- +8Price context36% below the 52-week high
- +15Cluster4 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
- -1510b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-024349, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 1, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $4.24 | $34 | 5,698,914 | May 9, 2025 |
| Apr 2, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $4.39 | $35 | 5,698,922 | May 9, 2025 |
| Apr 3, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $4.21 | $34 | 5,698,930 | May 9, 2025 |
| Apr 4, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $4.23 | $34 | 5,698,938 | May 9, 2025 |
| Apr 7, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $4.19 | $34 | 5,698,946 | May 9, 2025 |
| Apr 8, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $4.14 | $33 | 5,698,954 | May 9, 2025 |
| Apr 9, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $4.09 | $33 | 5,698,962 | May 9, 2025 |
| Apr 10, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $4.01 | $32 | 5,698,970 | May 9, 2025 |
| Apr 11, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $4.02 | $32 | 5,698,978 | May 9, 2025 |
| Apr 14, 2025 | POpen-market purchase Common Stock10b5-1 | +10 | $4.03 | $40 | 5,698,988 | May 9, 2025 |
| Apr 15, 2025 | POpen-market purchase Common Stock10b5-1 | +10 | $4.14 | $41 | 5,698,998 | May 9, 2025 |
| Apr 16, 2025 | POpen-market purchase Common Stock10b5-1 | +10 | $4.23 | $42 | 5,699,008 | May 9, 2025 |
| Apr 17, 2025 | POpen-market purchase Common Stock10b5-1 | +10 | $4.61 | $46 | 5,699,018 | May 9, 2025 |
| Apr 21, 2025 | POpen-market purchase Common Stock10b5-1 | +10 | $4.79 | $48 | 5,699,028 | May 9, 2025 |
| Apr 22, 2025 | POpen-market purchase Common Stock10b5-1 | +10 | $4.74 | $47 | 5,699,038 | May 9, 2025 |
| Apr 23, 2025 | POpen-market purchase Common Stock10b5-1 | +10 | $5.01 | $50 | 5,699,048 | May 9, 2025 |
| Apr 24, 2025 | POpen-market purchase Common Stock10b5-1 | +10 | $5.12 | $51 | 5,699,058 | May 9, 2025 |
| Apr 25, 2025 | POpen-market purchase Common Stock10b5-1 | +10 | $4.94 | $49 | 5,699,068 | May 9, 2025 |
| Apr 28, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $4.91 | $39 | 5,699,076 | May 9, 2025 |
| Apr 29, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $4.93 | $39 | 5,699,084 | May 9, 2025 |
| Apr 30, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $4.79 | $38 | 5,699,092 | May 9, 2025 |
Related signals
Other insiders at CUMBERLAND PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $4,516 1,372 shares | +0% | |
| 33Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $862 262 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | James Jones director | $862 262 shares | +1% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Caroline Young director | $398 121 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $5,872 1,712 shares | +1% | |
| 33Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $1,166 340 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | James Jones director | $1,166 340 shares | +1% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Caroline Young director | $578 168 shares | +1% | |
| 19Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $4,513 935 shares | +0% | |
| 19Weak | CUMBERLAND PHARMACEUTICALS INC | James Jones director | $807 168 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.